Semaglutide Training Courses in the UK: What the Evidence Says

What the STEP 1 trial and NICE guidance established about semaglutide

Any credible semaglutide training (for clinicians or patients) starts here. The STEP 1 phase 3 trial randomised nearly 2,000 adults with obesity or overweight plus at least one weight-related condition and no type 2 diabetes. Over 68 weeks, participants taking semaglutide 2.4mg weekly alongside lifestyle changes achieved an average weight reduction of around 15%, compared with roughly 2.4% on placebo. Those results were published in the STEP 1 paper in the New England Journal of Medicine and formed much of the evidence base NICE used when appraising the medicine.

NICE issued its recommendation for semaglutide (TA875) in March 2023, but with conditions that any good semaglutide training must convey clearly. The guidance recommends semaglutide only when used within a specialist weight management service providing multidisciplinary support, for a maximum of two years, and only for adults meeting defined BMI and comorbidity thresholds, broadly BMI 35 or above with at least one weight-related condition, though ethnic-background thresholds can be 2.5 kg/m² lower. If less than 5% weight loss is achieved after six months at the maintenance dose, continuing is reviewed. These are not small caveats. They shape how the medicine should be prescribed, monitored, and stopped, and they are the content that separates rigorous training from a surface-level overview. You can read NICE's full appraisal of semaglutide (TA875) directly on the NICE website.

The clinical picture has developed further since TA875. A higher 7.2mg maintenance dose received MHRA approval in early 2026, and trials at that dose reported average weight loss approaching 20.7%, narrowing the gap with tirzepatide results. If you are wondering whether you can take Trulicity and Wegovy together, that is one of the combination questions the evolving evidence base increasingly prompts, and it is worth understanding before discussing options with a prescriber. Understanding the trajectory of the evidence is part of what good clinician training covers.

What semaglutide training for healthcare professionals actually involves in the UK

A number of private training providers offer what they call wegovy training courses or semaglutide injection training programmes, typically aimed at nurses, pharmacists and aesthetic practitioners entering the weight management space. It is worth being clear about what these courses can and cannot confer.

In the UK, the authority to prescribe semaglutide as a prescription-only medicine sits with GMC-registered doctors and GPhC-registered Independent Prescribers. No commercial training course grants prescribing rights, that comes from a regulated prescribing qualification and registration with the appropriate body. What commercial courses can offer is practical knowledge: injection technique, titration schedules, patient selection criteria, managing common side effects (particularly the gastrointestinal profile that includes nausea, vomiting, diarrhoea and constipation), contraindications, and the clinical monitoring framework NICE and NHS England expect.

For prescribers already qualified, the NHS England guidance on weight management injections is the first reference point, not a commercial course. It covers contraception interactions, HRT considerations, pre-surgical disclosure, and the wraparound care model. If you are evaluating a training provider, check whether their content aligns with that guidance and with the MHRA's communications on this class of medicines. A course that does not address the pancreatitis Drug Safety Update, contraception interactions, or the counterfeit supply-chain risk is missing material that patients will ask about. There are also free options worth exploring: see our page on semaglutide training courses available online free for a breakdown of what those typically cover.

What patients searching for semaglutide training actually need

Many people searching for semaglutide training courses are not healthcare professionals at all. They are patients who have been prescribed (or are thinking about starting) semaglutide for weight management, and who want to feel confident before they inject for the first time. That is a completely reasonable instinct.

The practical knowledge a patient needs is more focused than a full clinical course: how to prepare and administer the pen correctly, which injection sites to rotate between (abdomen, thigh, and upper arm), how to store the medicine, what early side effects are normal, and what symptoms require urgent medical help. All of that information is in the Patient Information Leaflet that comes with every pen, and a good prescribing service will walk you through it before your first dose. Patients often find that pairing the leaflet with a focused read about what the medicine is actually doing (how GLP-1 receptor activation slows gastric emptying and reduces appetite signals) gives them much more confidence day to day. Our semaglutide overview and the broader guide to the full semaglutide dose course cover both the mechanism and the practical sequence.

One thing worth knowing: patients do not need to master a training curriculum before they start. They need a prescriber who has done that work already. A question our prescribers hear regularly is whether it is safe to do weight training on semaglutide, which tells you that most patient knowledge gaps are practical and situational, not theoretical. Good aftercare answers those questions as they arise, ideally on the same day you ask. If you are curious about the wider range of options available, the weight loss treatment overview puts semaglutide in context alongside other licensed approaches.

The supply-chain question no training course should skip

Any responsible semaglutide or wegovy training course (for clinicians or patients) must address where the medicine comes from. The MHRA has warned explicitly about counterfeit weight-loss pens circulating online and through social media. Fake pens have been found to contain insulin, with hospitalisations reported. In October 2025, the first illicit UK manufacturing site producing counterfeit tirzepatide pens was raided; by that point approximately 20 million doses of illegally traded weight-loss medicines (around £45 million street value) had been seized by enforcement. The lesson for anyone training in this area: the legitimate supply chain matters as much as correct injection technique. Semaglutide is a prescription-only medicine that can only legally be supplied following a clinical assessment, sellers offering it without a prescription, or via discount codes and social media posts, are a red flag, full stop. Report suspect sellers at the MHRA's Yellow Card scheme, which also accepts reports of suspected side effects. For patients specifically, the safest starting point is a GPhC-registered pharmacy you can verify on the register, our about us page explains how to do exactly that for nume.